Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019GlobeNewsWire • 10/11/19
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).GlobeNewsWire • 10/04/19
Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/26/19
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular DegenerationGlobeNewsWire • 09/18/19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior NotesGlobeNewsWire • 09/16/19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior NotesGlobeNewsWire • 09/12/19
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior NotesGlobeNewsWire • 09/11/19
Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal HemoglobinuriaGlobeNewsWire • 09/03/19